TABLE 2.
Amyloid + relative to amyloid- | AUC (95% CI) | |
Composite DSI | 0.78 (0.65–0.91) | |
Demographic | 0.54 (0.37–0.70) | |
Sex/Female | ↓ | 0.48 (0.35–0.60) |
Age | ↑ | 0.45 (0.28–0.61) |
Education (years) | ↓ | 0.59 (0.43–0.75) |
Cardiovascular | 0.60 (0.46–0.75) | |
Body mass index | ↓ | 0.65 (0.50–0.79) |
High blood pressure | ↑ | 0.49 (0.37–0.61) |
APOE (e4 carrier) | ↑ | 0.69 (0.56–0.82) |
Cognition | 0.65 (0.49–0.81) | |
mNTB Total | ↓ | 0.55 (0.38–0.72) |
mNTB Memory | ↑ | 0.54 (0.38–0.70) |
mNTB Processing speed | ↓ | 0.57 (0.41–0.73) |
mNTB Executive function | ↓ | 0.69 (0.53–0.84) |
MRI | 0.75 (0.61–0.89) | |
Volumes | 0.72 (0.57–0.88) | |
Total cortex | ↓ | 0.73 (0.59–0.88) |
Total gray matter | ↓ | 0.72 (0.57–0.88) |
Cerebellum cortex | ↓ | 0.69 (0.54–0.84) |
Thalamus proper | ↓ | 0.70 (0.55–0.85) |
Caudate | ↓ | 0.65 (0.49–0.81) |
Putamen | ↓ | 0.71 (0.56–0.87) |
Pallidum | ↓ | 0.61 (0.45–0.77) |
Brain Stem | ↓ | 0.61 (0.45–0.77) |
Hippocampus | ↓ | 0.70 (0.54–0.86) |
Amygdala | ↓ | 0.69 (0.53–0.85) |
Accumbens area | ↓ | 0.75 (0.62–0.89) |
Ventral diencephalon | ↓ | 0.68 (0.53–0.83) |
Cerebrospinal fluid | ↓ | 0.61 (0.44–0.78) |
Optic chiasm | ↓ | 0.60 (0.41–0.78) |
Total corpus callosum | ↓ | 0.62 (0.45–0.79) |
Visual MTA rating (Scheltens) | ↑ | 0.71 (0.59–0.84) |
AD-signature cortical thickness | ↓ | 0.65 (0.48–0.82) |
Upward arrow indicates the amyloid + group having a larger mean value. AUC values (95% confidence interval) are from 100 × 5-cross-validation. AUC, area under the receiver operating characteristic curve; DSI, disease state index; APOE, Apolipoprotein E; mNTB, modified neuropsychological test battery; MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy; AD, Alzheimer’s disease.